EVIDENCE PROFILE / PUBLISHED
CJC-1295 with DAC
Original CJC-1295 is a long-acting GHRH analogue using a drug-affinity-complex strategy. It should not be confused with short-acting modified GRF (1-29). Two small randomized ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases; biomarker changes did not establish a therapeutic outcome.
Evidence at a glance
- Human
- LimitedTwo small randomized studies in healthy adults, measuring hormone levels.
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. It is studied for prolonged growth-hormone and IGF-1 exposure in endocrine pharmacology.
Identity
Original CJC-1295 is a long-acting GHRH analogue using a drug-affinity-complex strategy. It should not be confused with short-acting modified GRF (1-29).
Biological mechanism or research interest
It is studied for prolonged growth-hormone and IGF-1 exposure in endocrine pharmacology.
Verified approved human uses
No approved human use was verified in the reviewed sources.
Investigational human evidence
Two small randomized ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases; biomarker changes did not establish a therapeutic outcome.
Popular claims versus demonstrated findings
Muscle, fat-loss, recovery, sleep, and anti-aging claims are not demonstrated by endocrine biomarker elevations.
Human versus animal or cell evidence
Analogue design and receptor pharmacology inform duration but not clinical benefit.
Limitations and known risks
FDA cites limited clinical data and serious adverse events including increased heart rate and systemic vasodilatory reaction; impurities and immunogenicity are concerns.
